Author

N. Rosen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Assay:DNA methylation· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

A. A. Jungbluth· 1 shared A. Baggiolini· 1 shared A. Barlas· 1 shared A. Iavarone· 1 shared A. J. Dannenberg· 1 shared A. Lasorella· 1 shared B. Desai· 1 shared B. S. Taylor· 1 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Jungbluth

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Tumorigenesis driven by the BRAF V600E oncoprotein requires secondary mutations that overcome its feedback inhibition of migration and invasion

s. gadal, J. A. Boyer, S. F. Roy, N. A. Outmezguine, M. Sharma, H. Li, N. Fan, E. Chan, Y. Romin, A. Barlas, Q. Chang, P. Pancholi, N. M. Timaul, M. Overholtzer, R. Yaeger, , N. Rosen

This study shows that BRAFV600E mutations inhibit cell migration and invasion through feedback inhibition of RAC1, requiring secondary mutations to overcome this block and enable tumorigenesis.

bioRxiv · Nov 21, 2023 · PreprintCancer Biology

Anatomic position determines oncogenic specificity in melanoma

J. M. Weiss, M. V. Hunter, N. M. Cruz, A. Baggiolini, M. Tagore, Y. Ma, S. Misale, M. Marasco, T. Simon-Vermot, N. R. Campbell, F. Newell, J. S. Wilmott, P. A. Johansson, J. F. Thompson, G. V. Long, , R. M. White

The paper shows that anatomic position influences oncogenic specificity in melanoma by identifying position-specific gene programs that interact with oncogenes like CRKL.

bioRxiv · Nov 14, 2020Cancer Biology

Mutant-selective Degradation by BRAF-targeting PROTACs

S. Alabi, S. Jaime-Figueroa, Z. Yao, Y. Gao, J. Hines, K. . T. G. Samarasinghe, L. Vogt, N. Rosen, C. M. Crews

This study develops BRAF-targeting PROTACs that degrade all BRAF mutants at sub-nanomolar concentrations while sparing wild-type RAF family members, showing in vivo efficacy and mechanistic insights.

bioRxiv · Aug 10, 2020Cancer Biology

Anti-tumor effects of an Id antagonist with no acquired resistance

P. M. Wojnarowicz, M. G. Escalono, Y.-H. Huang, B. Desai, Y. Chin, R. Shah, S. Xu, O. Ouerfelli, R. K. Soni, J. Philip, D. C. Montrose, J. H. Healey, V. K. Rajasekhar, W. A. Garland, L. Norton, , R. Benezra

This study demonstrates that AGX51, an Id antagonist, effectively inhibits tumor growth in multiple cancer models without inducing acquired resistance.

bioRxiv · Jan 6, 2020 · PreprintCancer Biology